- Home
- CDTX vs DRUG Comparison
CDTX vs DRUG Comparison
Compare CDTX & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDTX
- DRUG
- Stock Information
- Founded
- CDTX 2012
- DRUG 2019
- Country
- CDTX United States
- DRUG United States
- Employees
- CDTX N/A
- DRUG N/A
- Industry
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- DRUG Pharmaceuticals and Biotechnology
- Sector
- CDTX Health Care
- DRUG Health Care
- Exchange
- CDTX Nasdaq
- DRUG Nasdaq
- Market Cap
- CDTX 242.5M
- DRUG 260.6M
- IPO Year
- CDTX 2015
- DRUG N/A
- Fundamental
- Price
- CDTX $20.53
- DRUG $38.03
- Analyst Decision
- CDTX Strong Buy
- DRUG Buy
- Analyst Count
- CDTX 6
- DRUG 1
- Target Price
- CDTX $32.20
- DRUG $75.00
- AVG Volume (30 Days)
- CDTX 86.5K
- DRUG 169.6K
- Earning Date
- CDTX 11-07-2024
- DRUG 02-11-2025
- Dividend Yield
- CDTX N/A
- DRUG N/A
- EPS Growth
- CDTX N/A
- DRUG N/A
- EPS
- CDTX N/A
- DRUG N/A
- Revenue
- CDTX $44,653,000.00
- DRUG N/A
- Revenue This Year
- CDTX N/A
- DRUG N/A
- Revenue Next Year
- CDTX N/A
- DRUG N/A
- P/E Ratio
- CDTX N/A
- DRUG N/A
- Revenue Growth
- CDTX 44.48
- DRUG N/A
- 52 Week Low
- CDTX $10.00
- DRUG $0.93
- 52 Week High
- CDTX $24.99
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- CDTX 55.06
- DRUG 48.12
- Support Level
- CDTX $21.15
- DRUG $36.35
- Resistance Level
- CDTX $24.99
- DRUG $43.40
- Average True Range (ATR)
- CDTX 2.10
- DRUG 4.14
- MACD
- CDTX -0.15
- DRUG -0.49
- Stochastic Oscillator
- CDTX 41.16
- DRUG 12.81
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.